Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMed

Vascularization of Human iPSC-Derived Kidney Organoids Using Perfusion Culture, Pre-Vascularized Collagen Scaffolds, and Decellularized Extracellular Matrix.

Kearney H., Mazzoleni A., Martin I., Moroni L., Muraro MG., Mota C.

Laboratory Study on Systemic / IV, published in Adv Healthc Mater (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Adv Healthc Mater (2026)
Country
Germany
Reported sample size
—
Source database
PubMed
PMID
42576547
DOI
10.1002/adhm.71526

Abstract (original English)

Human induced pluripotent stem cell-derived kidney organoids represent promising in vitro models for studying kidney development and drug-induced toxicity, yet their lack of vasculature limits maturation and translational use. Here, we present a proof-of-concept co-culture platform to promote vascularization of kidney organoids by integrating stromal vascular fraction cells, collagen sponge scaffolds, porcine kidney decellularized extracellular matrix (dECM), and dynamic culture in a perfusion-based U-CUP bioreactor. We systematically evaluated the effects of serum supplementation, scaffold pre-vascularization, dECM encapsulation, and flow conditions on organoid-vascular integration. Low-level serum supplementation (1.5% FBS) sustained vascular networks without compromising organoid morphology. Perfusion supported vascular expansion; however, while a low flow rate comparable to interstitial tissue flow (0.01 mL/min) preserved organoid morphology and glomerular-like structures, a higher flow rate optimized for vascularization (0.47 mL/min) disrupted overall organoid architecture. Encapsulation within dECM preserved glomerular morphology and supported vascular infiltration, whereas co-culture with stromal vascular fraction cells enabled putative podocyte-endothelial interactions. Finally, exposure to the calcineurin inhibitor tacrolimus revealed dose-dependent cytotoxicity and ch

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research